Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.

Bcl-2 and its homologue, Bcl-x1, encode membrane-associated proteins that protect neoplastic cells from DNA damage-induced apoptosis, whereas Bax is a Bcl-2 antagonist that promotes cell death. In the present study, we examined the expression and regulation of these genes at both the mRNA and protein level in 22 pediatric acute lymphoblastic leukemia (ALL) cell lines, as well as their sensitivity to apoptosis after exposure to ionizing radiation (IR). Eleven of 22 lines expressed wild-type (wt) p53, 4 expressed mutant p53, and 7 did not express p53 (p53-null). Nine of 22 (41%) lines expressed Bcl-2; of these, 8 were wt-p53+ and 1 expressed mutant p53. Bcl-2 was not expressed in any p53-null lines. In contrast, all 22 lines were positive for Bcl-x1 and Bax, although expression level varied. Treatment with IR (10 Gy) induced both downregulation of Bcl-2 and upregulation of Bax at 2 to 5 hours post-IR in 5 of 8 (63%) wt-p53+ lines, leading to apoptosis. Conversely, lines that failed to both downregulate Bcl-2 and upregulate Bax after IR were resistant to apoptosis. Although levels of Bcl-x1 expression varied among the 22 lines, high levels of Bcl-x1 were observed in 5 of 7 (71%) p53- lines. There were no obvious changes in the expression of Bcl-x1 in these lines after IR. However, among the p53-null lines, resistance to IR was observed only in those expressing high levels of Bcl-x1. These results suggest that expression of Bcl-2 but not Bcl-x1 is p53-dependent and that IR-induced downregulation of Bcl-2 and upregulation of Bax occur in most wt-p53+ lines and are associated with radiosensitivity. Furthermore, high-level expression of Bcl-x1 occurs predominantly in p53-null lines and is associated with resistance to IR-induced apoptosis in these lines, indicating differential expression and regulation of Bcl-2 and Bcl-x1 in pediatric ALL.

[1]  C. Preudhomme,et al.  bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. , 1995, Leukemia.

[2]  C. Thompson,et al.  bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. , 1994, Development.

[3]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[4]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[5]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[6]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[7]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Alvarado,et al.  Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes , 1982 .

[9]  C. Croce,et al.  Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.

[10]  C. Thompson,et al.  Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. , 1995, Cancer research.

[11]  Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. , 1995 .

[12]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[13]  S. Korsmeyer Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[14]  E. White,et al.  Bcl-2 blocks p53-dependent apoptosis , 1994, Molecular and cellular biology.

[15]  R. Weichselbaum,et al.  Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. , 1995, Cancer research.

[16]  E. Cheng,et al.  Bax-independent inhibition of apoptosis by Bcl-XL , 1996, Nature.

[17]  G. Linette,et al.  Bcl-XL and Bcl-2 repress a common pathway of cell death , 1995, The Journal of experimental medicine.

[18]  M. Clarke,et al.  Bcl-XL protects cancer cells from p53-mediated apoptosis. , 1995, Oncogene.

[19]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[20]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[21]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[22]  D. Lane,et al.  Immunohistochemical detection of p53 and bcl‐2 proteins in non‐Hodgkin's lymphoma , 1993, Histopathology.

[23]  F. Alt,et al.  Bclx regulates the survival of double-positive thymocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. Behm,et al.  Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. , 1996, Blood.

[25]  Stephen,et al.  Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. , 1995, Blood.

[26]  K. Kohn,et al.  Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. , 1991, Cancer research.

[27]  E. Alnemri,et al.  Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. , 1992, Cancer research.

[28]  P. O'Connor,et al.  Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. , 1994, Oncogene.

[29]  J. Lotem,et al.  Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[31]  G. Janossy,et al.  Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. , 1995, Leukemia.

[32]  H. Findley,et al.  Effect of tumor necrosis factor-alpha on the proliferation of leukemic cells from children with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL): studies of primary leukemic cells and BCP-ALL cell lines. , 1991, Blood.

[33]  M. Clarke,et al.  Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation-induced cell death. , 1995, Carcinogenesis.

[34]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[35]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[36]  D. Fisher Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[37]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[38]  John Calvin Reed,et al.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  R. Weichselbaum,et al.  Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[40]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[41]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[42]  J. Hickman,et al.  Drug-target interactions: only the first step in the commitment to a programmed cell death? , 1991, British Journal of Cancer.

[43]  J. Lotem,et al.  Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.